SUBSCRIBERS

Drug developer Cennerv lodges prospectus for Catalist IPO

It specialises in treatments for depression, insomnia, dementia and autism

Published Fri, Sep 21, 2018 · 09:50 PM

Singapore

SINGAPORE-based biotech Cennerv Pharmaceuticals, a developer of drugs to treat central nervous system (CNS) disorders, lodged a preliminary prospectus on Wednesday for a planned initial public offering (IPO) on the Singapore Exchange's Catalist board.

Details of the pricing, amount to be raised and timing of the offering have not yet been announced. PrimePartners Corporate Finance is the sponsor, issue …

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes